Green Cross Corporation logo

Green Cross Corporation (006280)

Market Closed
7 Jul, 06:30
KRX SM KRX SM
130,200. 00
-1,200
-0.91%
1.54T Market Cap
- P/E Ratio
6,000% Div Yield
17,544 Volume
- Eps
131,400
Previous Close
Day Range
129,200 132,000
Year Range
111,800 181,800
Want to track 006280 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 28 days

Summary

006280 closed yesterday lower at ₩130,200, a decrease of 0.91% from Friday's close, completing a monthly increase of 2.44% or ₩3,100. Over the past 12 months, 006280 stock lost -27.47%.
006280 is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -784.74%, based on the last three reports. The next scheduled earnings report is due on Aug 05, 2025.
Green Cross Corporation has completed 1 stock splits, with the recent split occurring on Jun 07, 2013.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on KRX SM (KRW).

006280 Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

Green Cross Corporation Dividends

Green Cross Corporation logo
006280 6 months ago
Other
₩1,500 Per Share
Green Cross Corporation logo
006280 27 Dec 2023
Other
₩1,500 Per Share
Green Cross Corporation logo
006280 28 Dec 2022
Other
₩1,750 Per Share
Green Cross Corporation logo
006280 29 Dec 2021
Other
₩2,000 Per Share
Green Cross Corporation logo
006280 29 Dec 2020
Other
₩1,500 Per Share

Green Cross Corporation Earnings

5 Aug 2025 (In 4 weeks) Date
272.49
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
18 Mar 2025 Date
-
Cons. EPS
-
EPS
29 Jan 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS
Green Cross Corporation logo
006280 6 months ago
Other
₩1,500 Per Share
Green Cross Corporation logo
006280 27 Dec 2023
Other
₩1,500 Per Share
Green Cross Corporation logo
006280 28 Dec 2022
Other
₩1,750 Per Share
Green Cross Corporation logo
006280 29 Dec 2021
Other
₩2,000 Per Share
Green Cross Corporation logo
006280 29 Dec 2020
Other
₩1,500 Per Share
5 Aug 2025 (In 4 weeks) Date
272.49
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
18 Mar 2025 Date
-
Cons. EPS
-
EPS
29 Jan 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS

Green Cross Corporation (006280) FAQ

What is the stock price today?

The current price is ₩130,200.00.

On which exchange is it traded?

Green Cross Corporation is listed on KRX SM.

What is its stock symbol?

The ticker symbol is 006280.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 6,000%.

What is its market cap?

As of today, the market cap is 1.54T.

What is the earnings per share?

The EPS is 272.49.

When is the next earnings date?

The next earnings report will release on Aug 05, 2025.

Has Green Cross Corporation ever had a stock split?

Green Cross Corporation had 1 splits and the recent split was on Jun 07, 2013.

Green Cross Corporation Profile

Drug Manufacturers - Specialty & Generic Industry
Healthcare Sector
Mr. Il-Sup Huh Ph.D. CEO
KRX SM Exchange
KR7006280002 ISIN
KR Country
- Employees
27 Dec 2012 Last Dividend
7 Jun 2013 Last Split
- IPO Date

Overview

GC Biopharma Corp. is a prominent biopharmaceutical entity engaged in the innovation, development, and international distribution of pharmaceutical medicine. Founded in 1967 and headquartered in Yongin-Si, South Korea, the company has etched a global footprint, including a vast array of over-the-counter medications, treatments for various diseases, and vaccines. As a subsidiary of Green Cross Holdings Corporation, it has consolidated its reputation by offering a comprehensive suite of therapeutic solutions, underscoring its commitment to improving healthcare standards worldwide.

Products and Services

Acustop Cataplasma: An over-the-counter offering designed for analgesic and anti-inflammatory purposes, providing relief from pain and inflammation.

Kenhancer plaster: Targeted for anti-inflammatory effects, this product helps in reducing inflammation.

Zenol Cool Type and Zenol Mild Hot Type: Drugs formulated for anti-inflammatory purposes and pain relief, catering to varying patient preferences and conditions.

Albumin-GCC injection (inj.): Administered for conditions like hypoalbuminemia and shock due to acute hemorrhage, as well as in cases of low albumin synthesis.

Antithrombin-III (AT-III) inj.: Used in the treatment of hereditary antithrombin-III deficiency, a critical condition affecting the blood's ability to clot.

Facnyne inj.: A specialized formula for addressing hemophilia B, aiding in the management of this genetic bleeding disorder.

Fibrinogen: Offered for the treatment of hypofibrinogenemia and afibrinogenemia, focusing on conditions where fibrinogen levels in the blood are low.

Gamma Globulin: Essential for addressing hypogammaglobulinemia and agammaglobulinemia, diseases marked by an abnormally low presence of antibodies.

GCFLU Quadrivalent and GC FLU pre-filled syringe inj.: Vaccines formulated for the prevention of influenza, highlighting the company's role in infectious disease control.

GreenGene F inj.: A hemostatic agent for persons with hemophilia A, aimed at controlling bleeding symptoms.

GreenGene inj.: Another product for hemophilia A, focusing on treating bleeding episodes induced by the condition.

Greenplast Q: Designed for sealing tissues and closing wounds, facilitating the body's natural healing process.

Green-VIII inj.: Provides Hemophilia A patients with blood coagulation factor VIII, critical for blood clotting.

Hepabig inj.: Administered for hepatitis B, a liver infection caused by the hepatitis B virus (HBV).

Histobulin: Used in treating bronchial asthma, offering relief from chronic inflammatory disease of the airways.

Hunterase: A treatment for Hunter syndrome, a rare genetic disorder that affects the body's ability to break down certain sugars.

I.V. Hepabig inj.: Aimed at preventing the recurrence of hepatitis B in patients following liver transplantation.

I.V.-Globulin SN inj. 5%: Provides immune system support, crucial for fighting off infections.

Immuncell-LC: A treatment designed to address liver cancer, showcasing the company's commitment to oncological healthcare solutions.

Sero-Tet inj.: Used for the prophylaxis of tetanus and the reduction of tetanus symptoms, further emphasizing GC Biopharma's role in preventive healthcare.

Shinbaro: An agent for anti-inflammation and pain relief, specifically targeting osteoarthritis, a common form of arthritis.

Varicella Vaccine-GCC inj.: A vaccine for the prophylaxis of varicella, also known as chickenpox, a highly contagious viral infection.

Varicella-Zoster Immune Globulin-GCC inj.: Offers passive immunity to susceptible immunodeficient children exposed to varicella, preventing the development of the disease.

Contact Information

Address: 107, Ihyeon-ro 30beon-gil, Yongin-Si, South Korea
Phone: 82 3 1260 9300